Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gruben

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Arthritis Care & Research|June 9, 2022
Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational StudyBoulos Haraoui, Majed Khraishi, Denis Choquette, et al.
American Health & Drug Benefits|June 19, 2018
Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona RegistryDimitrios A Pappas, Robert A Gerber, Heather J Litman, et al.
Arthritis and Rheumatism|September 29, 2011
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugsRoy Fleischmann, Maurizio Cutolo, Mark C Genovese, et al.
The New England Journal of Medicine|June 19, 2014
Tofacitinib versus methotrexate in rheumatoid arthritisEun Bong Lee, Roy Fleischmann, Stephen Hall, et al.
Arthritis and Rheumatism|July 1, 2009
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placeboJoel M Kremer, Bradley J Bloom, Ferdinand C Breedveld, et al.
Lancet (London, England)|January 9, 2013
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialGerd R Burmester, Ricardo Blanco, Christina Charles-Schoeman, et al.
Arthritis and Rheumatism|October 19, 2011
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate aloneJoel M Kremer, Stanley Cohen, Bethanie E Wilkinson, et al.
Patient Preference and Adherence|February 6, 2020
Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-MakingPeter C Taylor, Neil Betteridge, T Michelle Brown, et al.
Annals of Internal Medicine|September 13, 2013
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trialJoel Kremer, Zhan-Guo Li, Stephen Hall, et al.
The Journal of Rheumatology|April 3, 2014
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studiesJürgen Wollenhaupt, Joel Silverfield, Eun Bong Lee, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Arthritis Care & Research|June 9, 2022
Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational StudyBoulos Haraoui, Majed Khraishi, Denis Choquette, et al.
American Health & Drug Benefits|June 19, 2018
Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona RegistryDimitrios A Pappas, Robert A Gerber, Heather J Litman, et al.
Arthritis and Rheumatism|September 29, 2011
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugsRoy Fleischmann, Maurizio Cutolo, Mark C Genovese, et al.
The New England Journal of Medicine|June 19, 2014
Tofacitinib versus methotrexate in rheumatoid arthritisEun Bong Lee, Roy Fleischmann, Stephen Hall, et al.
Arthritis and Rheumatism|July 1, 2009
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placeboJoel M Kremer, Bradley J Bloom, Ferdinand C Breedveld, et al.
Lancet (London, England)|January 9, 2013
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialGerd R Burmester, Ricardo Blanco, Christina Charles-Schoeman, et al.
Arthritis and Rheumatism|October 19, 2011
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate aloneJoel M Kremer, Stanley Cohen, Bethanie E Wilkinson, et al.
Patient Preference and Adherence|February 6, 2020
Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-MakingPeter C Taylor, Neil Betteridge, T Michelle Brown, et al.
Annals of Internal Medicine|September 13, 2013
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trialJoel Kremer, Zhan-Guo Li, Stephen Hall, et al.
The Journal of Rheumatology|April 3, 2014
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studiesJürgen Wollenhaupt, Joel Silverfield, Eun Bong Lee, et al.
Pageof 7